So essentially our CMO Kellum has been with us....Since 2012. First as a shareholder of Alter-cyte and more importantly as our DSMB lead screwtinizing every scrap of data from the phase 3 ( advertised Failure, but not really ) Euphrates....
Hmmmmm....
Someone should ask him, Toray, Spectral or maybe the FDA why they didnt expand on the phase 2 Euphas trial ( the one so successful they had to stop it ). Id ask an "expert" but the Euphas phase 2( 21% absolute benefit ) does seem to fit that gut dysbiosis / culture negative / translocation tree our old leadership barked up 20 years ago.
The next time someone says, "the trial would already be done now except for this little guy"... they should just show this symbol "$"
The fact we are "playing the tax loss card" 5+ years later on the Canadien social stock media feed should help you value your 20 cent 5 FDA approval "fare-ee tale"
Bon appy and do bite down hard ;- )
Tom